Endocrinology

Myeloma

Questions discussed in this category

Does the presence of osteoporosis change the extent of workup that should be performed for an older patient with otherwise serologically low-risk MGUS?

Would your considerations change for a man vs a woman?

1 Answer available

For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?

For pts w/ eGFR between 30-60

1 Answer available

Do you routinely offer a bisphosphonate or denosumab to multiple myeloma patients without skeletal lesions?

Recommendations in guidelines are discordant (ASCO vs NCCN vs UptoDate).

2 Answers available

For patients with cancer receiving a bone-modifying agent (bisphosphonate or denosumab) who suffer a fracture requiring stabilization or reconstruction, how do you manage the bone-modifying agent peri-operatively?

Is there concern for impaired healing? Do you pause therapy and for how long?

1 Answer available

Is there any role for bisphosphonate or alternative bone-modifying agents use in SMM in the absence of other indications for its use?

1 Answer available

Papers discussed in this category

Leuk. Lymphoma, 2011 Feb 08

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.

Cancer,

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.

Blood, 2013-10-24

The impact of response on bone-directed therapy in patients with multiple myeloma.

The Lancet. Oncology, 2011-08

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.

The Lancet. Oncology, 2018-03

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

Blood advances, 2017 Dec 21

Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Related Topics in Endocrinology